GENTAMICIN SULFATE- gentamicin sulfate solution/ drops RPK Pharmaceuticals, Inc.

Gentamicin Sulfate Ophthalmic Solution, USP 0.3% (Sterile) Rx only

DESCRIPTION

Gentamicin sulfate ophthalmic solution, USP is a sterile, aqueous solution buffered to approximately pH 7.0 and formulated for ophthalmic use.

Each mL contains:


Active: gentamicin sulfate, USP (equivalent to 3 mg gentamicin).

Inactives: dibasic sodium phosphate, sodium chloride, monobasic sodium phosphate, purified water. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH (6.5 - 7.5).

Preservative: benzalkonium chloride 0.01%.

Gentamicin is an aminoglycoside antibiotic obtained from cultures of *Micromonospora purpurea*. It is a mixture of the sulfate salts of gentamicin C1, C2, C1a and C2a. All three components appear to have similar antimicrobial activity. Gentamicin sulfate occurs as a white to buff powder and is soluble in water and insoluble in alcohol.

The structural formula is as follows:



CLINICAL PHARMACOLOGY

Microbiology

Gentamicin sulfate is active *in vitro* against many strains of the following microorganisms:

Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

INDICATIONS AND USAGE

Gentamicin sulfate ophthalmic solution is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms:

Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

CONTRAINDICATIONS

Gentamicin sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS

NOT FOR INJECTION INTO THE EYE

Gentamicin sulfate ophthalmic solution is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

PRECAUTIONS

General

Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible organisms including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician. If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation and appropriate therapy should be instituted.

Information for Patients

To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

Carcinogenesis, Mutagenesis, Impairment of Fertility

There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

Pregnancy

Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

ADVERSE REACTIONS

Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.

The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia.

Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

Instill one or two drops into the affected eye(s) every four hours. In severe infections dosage may be increased to as much as two drops every hour.

HOW SUPPLIED

Product: 53002-9293

NDC: 53002-9293-1 5 mL in a BOTTLE, DROPPER / 1 in a CARTON

Gentamicin 0.03% Ophthalmic Solution

		25323		BLLINGINGLY SCHOOL INCOME	коси завес-наче-и поли сименователя интипаконотика на начена и обрати со политика наче и обратика на начена на политика и и обратика интерновал обрато Сало Спро Nan	REFERENCES INFORMATION E POISSIN FOR WORKTOWS ILL MEDICATIONS OF THE INFORMATION OF MEDICAL STRUMETER ON THE IT TANKING AND
CLINC NAME GOES HERE Prescrive Xuns			Fini, GENTANICH 2.35 GPVTHAL BOLM	PRESCRIBER NAME	DATE	
	A DAY OR AS	DER IS DER ITT ORLYTO PERFERT CONTRACTANTON DE NOT LET DER DETLE TE FORCE TER FOR, YTT LED OR ANT OTHER SHEFACT. Perfections	A DAY OR AS DIRECTED.	A DAY OR AS DIRECTED.	A DAY OR AS DIRECTED.	A DAY OR AS DIRECTED.

GENTAMICIN SULFATE									
gentamicin sulfate solution/ drops									
Ρ	roduct Info	rmation							
D	roduct Type		HUMAN PRESCRIPTION	Item Code NDC:53002-92)2-9293	93(NDC:24208-	
	louuce type		DRUG	(Source) 580)					
R	oute of Admir	nistration	OPHTHALMIC						
Active Ingredient/Active Moiety									
G			386QRLV) (GENTAMICIN - UN	III-T670\//8IKC		AMICIN	ngtn	Strength 3 mg in 1 mL	
G				1. 1 02 9 V40ING	, GENT			5 mg m i m	
Inactive Ingredients									
Ingredient Name Stre						Strength			
SODIUM CHLORIDE (UNII: 451W47IQ8X)									
SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM (UNII: 3980JIH2SW)									
	ATER (UNII: 059								
HYDROCHLORIC ACID (UNII: QTT17582CB)									
		(IDE (UNII: 55X04							
BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7) SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM (UNII: GR686LBA74)									
50		IATE, DIBASIC,		GROSOLDA/4)					
D	ackaging								
	ackaging					a. Chairt	Mari		
#	Item Code	Pa	ackage Description	M	arketin Dat	-	Mari	keting End Date	
1	NDC:53002- 9293-1	1 in 1 CARTON		07/	01/2022				
1		5 mL in 1 BOTT Combination Pro	LE, DROPPER; Type 0: Not a oduct						
M	larketing	Informat	ion						
-									

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
ANDA	ANDA064048	05/11/1994		
ANDA	ANDA004048	03/11/1994		

Labeler - RPK Pharmaceuticals, Inc. (147096275)

Establishment								
Name	Address	ID/FEI	Business Operations					
RPK Pharmaceuticals, Inc.		147096275	RELABEL(53002-9293)					

Revised: 11/2023

RPK Pharmaceuticals, Inc.